This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
A-PHP: Difference between revisions
>Unity No edit summary |
>Josikins |
||
| Line 17: | Line 17: | ||
==Pharmacology== | ==Pharmacology== | ||
The mechanism of action is unknown for α-PHP. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] MDPV, which acts as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has been conducted. | The mechanism of action is unknown for α-PHP. Aside from a substantially shorter duration, it is believed to act similarly to the [[designer drug]] MDPV, which acts as a potent [[norepinephrine]]-[[dopamine]] [[reuptake inhibitor]] (NDRI),<ref>http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602954</ref> although no substantial research on the pharmacology of this compound has been conducted. | ||
This means it may effectively boost the levels of the norepinephrine and dopamine neurotransmitters in the brain by binding to and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the brain, resulting in [[stimulation|stimulating]] and [[physical euphoria|euphoric]] effects. | |||
==Subjective effects== | ==Subjective effects== | ||